home / stock / lly / lly news


LLY News and Press, Eli Lilly and Company From 04/26/24

Stock Information

Company Name: Eli Lilly and Company
Stock Symbol: LLY
Market: NYSE
Website: lilly.com

Menu

LLY LLY Quote LLY Short LLY News LLY Articles LLY Message Board
Get LLY Alerts

News, Short Squeeze, Breakout and More Instantly...

LLY - EOI: 9% Plus Income, Paid Monthly, And Solid Past Record

2024-04-26 09:00:00 ET Summary Eaton Vance Enhanced Equity Income Fund is a closed-end fund that mainly invests in the equities of U.S. listed companies. The EOI CEF has a pretty strong long-term record of performance, even though it tends to underperform the S&P 500 slightly....

LLY - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

LLY - Novo Nordisk comes under Senate probe over pricing for weight loss drugs

2024-04-24 15:42:21 ET More on Novo Nordisk Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront 3.6M Medicare patients could qualify f...

LLY - Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...

LLY - 3.6M Medicare patients could qualify for Wegovy coverage: report

2024-04-24 10:27:55 ET More on Novo Nordisk Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront TikTok to restrict weight loss drug pr...

LLY - Artisan International Fund Q1 2024 Commentary

2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...

LLY - Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

2024-04-24 06:40:00 ET Eli Lilly 's (NYSE: LLY) Zepbound has shown it has what it takes to become a blockbuster. The weight-loss drug, following regulatory approval late last year, brought in $175 million in revenue in just its first few weeks on the market. Doctors and their patien...

LLY - JGRO: Promising ETF In The Growth Category

2024-04-24 05:09:27 ET Summary JPMorgan Active Growth ETF is an actively managed ETF focused on companies with above-average earnings growth and leading competitive positions. The portfolio is heavily invested in large companies of the technology, consumer discretionary and commun...

LLY - Madison Sustainable Equity Fund Q1 2024 Investment Strategy Letter

2024-04-24 04:30:00 ET Summary Equity markets had a solid start to the year, with the S&P 500 up 10.6%. The Madison Sustainable Equity Fund lagged the S&P 500 for the first quarter. As we exited the quarter, sticky inflation began to put into question the timing and number...

LLY - 3 Potential Biopharma Buyout Targets

2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...

Previous 10 Next 10